Timothy L. Moore

Timothy L. Moore (board member) discloses dealings in 3 companies, chiefly Biolife Solutions Inc, Cerus Corp and Allogene Therapeutics, Inc. We count 18 filings; the first trade dates from 1 June 2021 and the latest from 6 October 2026.

Sales make up the whole of the open-market record (1 sale, €25k). The rest of the record consists of 14 share grants and 2 option exercises.

On 8 October 2026 came the latest disclosure, a transaction in Biolife Solutions Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.